171 related articles for article (PubMed ID: 25684022)
1. PDK1 disruptors and modulators: a patent review.
Hossen MJ; Kim SC; Yang S; Kim HG; Jeong D; Yi YS; Sung NY; Lee JO; Kim JH; Cho JY
Expert Opin Ther Pat; 2015 May; 25(5):513-37. PubMed ID: 25684022
[TBL] [Abstract][Full Text] [Related]
2. A patent update on PDK1 inhibitors (2015-present).
Sestito S; Rapposelli S
Expert Opin Ther Pat; 2019 Apr; 29(4):271-282. PubMed ID: 30897008
[TBL] [Abstract][Full Text] [Related]
3. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.
Medina JR
J Med Chem; 2013 Apr; 56(7):2726-37. PubMed ID: 23448267
[TBL] [Abstract][Full Text] [Related]
4. PDK1 inhibitors.
Barile E; De SK; Pellecchia M
Pharm Pat Anal; 2012 May; 1(2):145-63. PubMed ID: 24236780
[TBL] [Abstract][Full Text] [Related]
5. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
[TBL] [Abstract][Full Text] [Related]
7. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.
Rettenmaier TJ; Fan H; Karpiak J; Doak A; Sali A; Shoichet BK; Wells JA
J Med Chem; 2015 Oct; 58(20):8285-8291. PubMed ID: 26443011
[TBL] [Abstract][Full Text] [Related]
9. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
10. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
11. Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents.
Mansi I; Al-Sha'er MA; Mhaidat N; Taha M
Anticancer Agents Med Chem; 2020; 20(4):476-485. PubMed ID: 31889497
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
13. A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014.
Filipski KJ; Pfefferkorn JA
Expert Opin Ther Pat; 2014 Aug; 24(8):875-91. PubMed ID: 24821087
[TBL] [Abstract][Full Text] [Related]
14. Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma.
Sestito S; Daniele S; Nesi G; Zappelli E; Di Maio D; Marinelli L; Digiacomo M; Lapucci A; Martini C; Novellino E; Rapposelli S
Eur J Med Chem; 2016 Aug; 118():47-63. PubMed ID: 27123901
[TBL] [Abstract][Full Text] [Related]
15. Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1.
Hindie V; Lopez-Garcia LA; Biondi RM
Methods Mol Biol; 2012; 928():133-41. PubMed ID: 22956138
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule inhibitors of PDK1.
Peifer C; Alessi DR
ChemMedChem; 2008 Dec; 3(12):1810-38. PubMed ID: 18972468
[TBL] [Abstract][Full Text] [Related]
17. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.
Bobkova EV; Weber MJ; Xu Z; Zhang YL; Jung J; Blume-Jensen P; Northrup A; Kunapuli P; Andersen JN; Kariv I
J Biol Chem; 2010 Jun; 285(24):18838-46. PubMed ID: 20385558
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Zask A; Verheijen JC; Richard DJ
Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
[TBL] [Abstract][Full Text] [Related]
19. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
